This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
About us
We are a biopharmaceutical company devoted to the development of a new class of therapeutics to address unmet medical needs in cancer.
Libera Bio aims at changing cancer therapy by allowing biologics to cross the cell membrane and reach “undruggable” intracellular targets: the “Holy Grail” in oncology
Libera Bio leverages its unique proprietary nanotechnology to hold and protect biologicals (e.g., antibodies) in the blood stream following IV administration and to deliver them intracellularly to tumor cells and to metastatic cells
Libera Bio seeks to maximize the use of its technology with oncology biopharma partners, to offer patients new oncology breakthrough treatments based on intracellular delivery of biologics
Our team
Discover our MPN Technology®
Our patented MPN Technology® enables the discovery and development of new compounds involving intracellular biologics, especially monoclonal antibodies (mAbs), to successfully engage previously undruggable targets.
Programs
Libera Bio is dedicated to developing a new class of therapeutics addressing intracellular disease targets, with an initial focus on cancer. It leverages its Multifunctional Polymeric Nanoparticles (MPN Technology®) to deliver large molecules such as antibodies, with the optional co-delivery of a small molecule agent.
Through independent efforts and strategic collaborations with leading biotech partners, the company is actively advancing potential treatments spanning various types of cancer. Its streamlined and scalable platform has been meticulously designed to seamlessly bridge the gap from preclinical research to clinical development, ensuring efficiency and effectiveness in our mission to bring transformative therapies to those in need
Partnering
Libera Bio is open to licensing or partnering its MPN Technology® to develop or co-develop new cancer treatments based either on biologics or small molecules. The technology can encapsulate a range of therapeutic payloads, such as monoclonal antibodies, antibody fragments/nanobodies, small molecules, and PROTACs/AbTACs, which creates a broad scope for potential partnerships.
Partnering contact: Olivier Jarry, partnering@liberabio.com
Supported by
Investors
IÑAKI BERENGUER
Francisco Rañal
Inquiries from potential investors in the next round of funding of Libera Bio are welcome.
Investors Relations: partnering@liberabio.com
Awards
Collaborators
EUROPE
Edificio Emprendia
Avenida do Mestre Mateo 2
15706 Santiago de Compostela, A Coruña (Spain)
NORTH AMERICA
15 Rockridge Rd
Larchmont NY 10538-3918
(USA)